• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.223-223
• /
• 1994

FDA가 공인한 항 HIV제로서 사용중인 AZT나 DDI와 같은 화합물은 장기 투여로 심각한 부작용들이 나타나고 있다. 그래서 기존의 activity를 가진 nucleoside류의 sugar 부분에 새로운 base 즉, 5-ethoxymethyl uracil을 축합, 3'-azido-2',3'-dideoxy-5-ethoxy-methyl uridine, 2',3'-aideoxy-3'-fluoro-5-ethoxymethyl uridine과 2',3'-dideoxy-5-ethoxymethyl uridine들을 합성, 구조활성 상관관계를 검토하였다. 이들의 합성은 먼저 적절한 group으로 sugar의 -OH group을 보호한후 uracil류와 반응, uridine 유도체를 먼저 합성하였다. 각각의 uridine 유도체들의 5-위치에 ethoxymethyl group을 도입하기 위해 formalin과 반응시킨후 5-hydroxy-methyl group을 도입하고 산촉매 하에 ethanol과 반응, ethyl ether류를 합성하였다.

• Biomolecules & Therapeutics
• /
• 제21권2호
• /
• pp.170-172
• /
• 2013

The pyrimidine nucleoside uridine has recently been reported to have a protective effect on cultured human corneal epithelial cells, in an animal model of dry eye and in patients. In this study, we investigate the pharmacokinetic profile of uridine in rabbits, following topical ocular (8 mg/eye), oral (450 mg/kg) and intravenous (100 mg/kg) administration. Blood and urine samples were serially taken, and uridine was measured by high-performance liquid chromatography-tandem mass spectrometry. No symptoms were noted in the animals after uridine treatment. Uridine was not detected in either plasma or urine after topical ocular administration, indicating no systemic exposure to uridine with this treatment route. Following a single intravenous dose, the plasma concentration of uridine showed a bi-exponential decay, with a rapid decline over 10 min, followed by a slow decay with a terminal half-life of $0.36{\pm}0.05$ h. Clearance and volume of distribution were $1.8{\pm}0.6$ L/h/kg and $0.58{\pm}0.32$ L/kg, respectively. The area under the plasma concentration-time curves (AUC) was $59.7{\pm}18.2{\mu}g{\cdot}hr/ml$, and urinary excretion up to 12 hr was ~7.7% of the dose. Plasma uridine reached a peak of $25.8{\pm}4.1{\mu}g/ml$ at $2.3{\pm}0.8$ hr after oral administration. The AUC was $79.0{\pm}13.9{\mu}g{\cdot}hr/ml$, representing ~29.4% of absolute bioavailability. About 1% of the oral dose was excreted in the urine. These results should prove useful in the design of future clinical and nonclinical studies conducted with uridine.

• 생명과학회지
• /
• 제9권1호
• /
• pp.63-68
• /
• 1999

5-halogen substituted uridine, amino acid, peptide 및 penicillin G의 5'-amino -5' -deoxyuridine con-jugates, 5'-monophosphate uridine 유도체, 5'-monophosphate uridine -fat쇼 acid 유도체와 같은 nu-cleoside 화합물들을 화학적으로 합성한 후 이들의 항진균, 항균 및 항암 활성을 측정하였다. 5-Bromo-2',3'-O-isopropylideneuridine(6)은 Trichophyton rubrum의 성장을 억제하였다(MIC: $0.2{\mu}$g/ml). 5'-Amino-5' -deoxyuridine -penicillin G(19), 5'-amino-5'-deoxyuridine-cyclo(Phe -Asp)(20), 5-iodo-5'-amino -5' -deoxyuridine-penicillin G(22)는 항균적이었고(S. aureus에 대해 MIC가 $6.25{\mu}$g/ml) 뒤의 두 nucleoside 화합물은 항암 작용이 가장 강한 유도체이었다(L5178Y murine lymphoma cell에 대한 $IC_{50}$이 $6.5{\mu}$g/ml).

• Archives of Pharmacal Research
• /
• 제21권4호
• /
• pp.465-469
• /
• 1998

The search for platinum (II)-based compounds with improved therapeutic properties was prompted to design and synthesize a new family of water-soluble, third generation cis-diaminedichloroplatinum (II) complexes linked to uracil and uridine. Six heretofore unreported uracil and uridine-platinum (II) complexes are; [N-(uracil-5-yl-methyl)ethane-1,2-di-amine]dichloroplatinum (II) (3a), [N-(uracil-6-yl-methyl)ethane-1,2-diaminel dichloroplatinum (II) (3b), t[N-($2^1$, $3^1$,$5^1$-tri-O-acetyl)uridine-5-yl-methyl] ethane-1,2-diamineldichloroplatinum (II) (6a), {[N-($2^1$,$3^1$, $5^1$-tri-O-acetyl) uridine-6-yl-methyl]ethane-1,2-diamine)dichloroplatinum (II) (6b),[N-(uridine- 5-yl-methyl)ethane-1,2-diamine]dichloroplatinum (II) (7a), [N-(uridine-6-yl- methyl)ethane-1,2-diamine]dichloroplatinum (II) (7b). These analogues were prepared from the key starting materials, 5-chloromethyluracil (1a) and 6-chloromethyluracil (1b) which were reacted with ethylenediamine to afford the respective 5-[(2-aminoethyl)aminol methyluracil (2a) and 6-[(2-aminoethyl)amino]methyluracil (2b). The cis-platin complexes 3a and 3b were obtained through the reaction of the respective 2a and 2b with potassium tetrachloroplatinate (II). The heterocyclic nucleic acid bases 1a and 1b were efficiently introduced on the .betha.-D-ribose ring via a Vorbruggen-type nucleoside coupling procedure with hexamethyldisilazane, trimethylchlorosilane and stannic chloride under anhydrous acetonitrile to yield the stereospecific .betha.-anomeric 5-chloromethyl- $2^1$,$3^1$,$5^1$-tri-O-acetyluridine (4a) and 6-chloromethyl-$2^1$,$3^1$,$5^1$-tri-O-acetyluridine (4b), respectively. The nucleosides 4a and 4b were coupled with ethylenediamine to provide the respective 5-[(amino-ethyl)aminolmethyl-$2^1$,$3^1$,$5^1$-tri-O-acetyluridine (5a) and 6-[(aminoethyl)amino] methyl-$2^1$,$3^1$,$5^1$-tri-O-acetyluridine (5b). The diamino-uridines 5a and 5b were reacted with potassium tetrachloroplatinate (II) to give the novel nucleoside complexes, 6a and 6b, respectively which were deacetylated into the free nucleosides, 7a and 7b by the treatment with CH$_{3}$ONa. The cytotoxic activities were evaluated against three cell lines (FM-3A, P-388 and J-82) and none of the synthesized compounds showed any significant activity.

• 대한화학회지
• /
• 제45권4호
• /
• pp.312-317
• /
• 2001

7'-Aldehyde-nucleoside 유사체(2a, 2c)을 6-N-benzoyl-2',3'-O-isopropylideneadenosiner과 uridine으로부터 합성하였다. 2와 Wittig reagent인 ethoxycarbonylmethylene을 축합시켜 ethoxycarbonyl group을 갖는 탄소수를 증가시킨 공액 이중 결합을 지닌 nucleosi de 유사체, ethyl-1',5',6',7',8'-pentadeoxy-1'-(adenin-9-yl)-$\beta$-D-ribo-nnona-5'(E).7'(E)-dienofuranuronate(4b), ethyl-1',5',6',7',8'-pentadeoxy-1'-(uracyl-1-yl)-$\beta$-D-ribo-nona-5'(E),7'(E)-dienofuranuronate(4c)을 얻었다. 또한 2와 CBr4, Ph3P을 반응시켜 공액 이중 결합을 지닌 9-[8',8'-dibromo-5',6',7',8'-tetradeoxy-$\beta$-D-ribo-octa-5'(E),7'(E)-diene]nucleosides (6b,6c) 유사체를 각각 합성하였다.

• 미생물학회지
• /
• 제29권6호
• /
• pp.353-360
• /
• 1991

5-substituted uridine(I,Br,Cl), 5'-amino-5'-deoxyuridine conjugates of amino acid, peptide and penicillin G, 5'-monophosphate uridine derivatives and 5'-monophosphate-fatty acid detrivatives were chemically synthesized. Their biological activities were determined as MIC and IC/sub 50/ unit against various pathogenic microorganisms in vitro. 5'-amino-5'-deoxyuridine-cyclo(Phe-Asp)(23), 5-iodo-5'-amino-deoxyuridine-penicillin G(26) were the most efficient; their IC/sub 50/ against L5178Y murine lymphoma cell was 6.5 h/ml, MIC against S. aureus (+) and E. coli (-) was 6.25 g/ml. MIC of 5-bromo-2', 3'-O-isopropylideneuridine(6) against Trichophyton rubrum was 0.2 g/ml. And 5'-monophosphate derivatives are more active than simple uridine derivatives, suggesting other modified nucleoside 5'-phosphate may be worthwhile examing further as a new prodrugs.

• 한국원자력학회:학술대회논문집
• /
• 한국원자력학회 2001년도 춘계학술발표회요약집
• /
• pp.444.2-444
• /
• 2001

• 대한약리학회지
• /
• 제24권1호
• /
• pp.11-16
• /
• 1988

Uridine phosphorylase 효소의 강력한 억제제로 개발된 유리딘 비고리핵산들(Benzylacyclouridine: BAU, HM-BAU, suc-BAU, BBAU, HM-BBAU, suc-BBAU, and BBBAU)이 uridine,의 사람 적혈구 내로의 수송(Zero-trans influx)에 미치는 영향에 관하여 rapid sampling technique을 이용하여 고찰하였다. 이 실헙에서 유리딘-비고리핵산들은 parent compounds인 BAU, BBAU와 같이 uridine 수송에 상경적인 억제작용을 보였다. 그러나 suc-BBAU와 BBBAU는 비상경적인 억제요소도 나타냈다. Uridine 수송억제제로서 효력의 크기는 $BBAU{\sim}HM-BBAU{\sim}suc-BBAU>BAU{\sim}suc-BAU{\sim}HM-BAU$이었으며, 그 억제상수는 각각 19, 23, 38, 112, 124, 174 그리고 $176\;{\mu}M$이었다. 본 실험 결과에서는 uridine 수송에 있어서 BAU의$C_5$ 자리의 친지방성 치환 group의 크기에 따라 억제효력이 다른 것이 시사되었다.

• 생약학회지
• /
• 제16권4호
• /
• pp.239-242
• /
• 1985

The anion of $6-benzenesulfonyl-3-O-benzyl-6-deoxy-1,2-O-isopropylidene-{\alpha}-d-glucofuranose$ was stable and reacted with carbon electrophiles to give higher-carbon sugars. Reactions of uridine 5'-aldehyde with phosphoranes afforded heptofuranose nucleosides.

• 생명과학회지
• /
• 제9권1호
• /
• pp.58-62
• /
• 1999

몇가지 nucleoside 5'-monophosphate 유도체들과 지질 친화성을 증가시킨 nucleoside 5'-(3-pyridinyl carbonyl)monophosphate 유도체들을 합성한 후 Mouse leukemia P388, Murine mammary carcinoma FM3A, Human histiocytic lymphoma U937 세포들에 대해 시험관내에서 항암활성을 MTT를 이용한 방법으로 나타내었다. 그 결과 uridine 5'-(3-pyridinylcarbonyl) monophosphate(7)와 2',3'-didehydro-3'-deoxythymidine-5' -(3-pyridinylcarbonyl) monophoshate(8)의 inhibition이 uridine 5'-monophosphate(1)와 2',3'-didehydro-3'-deoxythymidine-5'-monophosphate(4) 보다 각각 증가하였다. 이는 nucleoside 5'-(3-pyridinylcarbonyl) monophosphate 유도체들이 임상적 한계를 극복할 수 있는 가능성을 보인 것이다.